PRODUCT PROFILE( LATE STAGE): MEN QUAD TT PRODUCT PROFILE( LATE STAGE): MENABCW-135Y
LIST OF FIGURES Figure 1: Meningococcal vaccines market value across the US and five major EU markets, by country, 2016 – 25 Figure 2: Total sales of meningococcal vaccines in the US, by risk group, 2016 – 25 Figure 3: Total sales of MenB vaccines across the US and five major EU markets, by country, 2016 – Figure 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class, 2016 – 25 Figure 5: Patient-based forecasting methodology for meningococcal vaccines Figure 6: Price sources and calculations in the EU, by country Figure 7: Total sales of meningococcal vaccines in the US, by risk group, 2016 – 25 Figure 8: Total sales of meningococcal vaccines in the US, by class, 2016 – 25 Figure 9: Meningococcal vaccination coverage in the US, by risk group, 2016 – 25 Figure 10: Total sales of meningococcal vaccines in France, by class, 2016 – 25 Figure 11: Meningococcal vaccination coverage in France, by risk group, 2016 – 25 Figure 12: Total sales of meningococcal vaccines in Germany, by class, 2016 – 25 Figure 13: Meningococcal vaccination coverage in Germany, by risk group, 2016 – 25 Figure 14: Total sales of meningococcal vaccines in Italy, by class, 2016 – 25 Figure 15: Meningococcal vaccination coverage in Italy, by risk group, 2016 – 25 Figure 16: Total sales of meningococcal vaccines in Spain, by class, 2016 – 25 Figure 17: Meningococcal vaccination coverage in Spain, by risk group, 2016 – 25 Figure 18: Total sales of meningococcal vaccines in the UK, by class, 2016 – 25 Figure 19: Meningococcal vaccination coverage in the UK, by risk group, 2016 – 25 Figure 20: Bexsero for meningococcal disease – SWOT analysis Figure 21: Menactra for meningococcal disease – SWOT analysis Figure 22: Menveo for meningococcal disease – SWOT analysis Figure 23: Nimenrix for meningococcal disease – SWOT analysis Figure 24: Trumenba for meningococcal disease – SWOT analysis Figure 25: Men Quad TT for meningococcal vaccination – SWOT analysis Figure 26: MenABCW-135Y for meningococcal vaccination – SWOT analysis
LIST OF TABLES Table 1: Meningococcal vaccines market value across the US and five major EU markets, by country($ m), 2016 – 25 Table 2: Total sales of meningococcal vaccines in the US, by risk group($ m), 2016 – 25 Table 3: Total sales of MenB vaccines across the US and five major EU markets, by country($ m), 2016 – 25 Table 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class($ m), 2016 – 25 Table 5: Recommendations for meningococcal vaccination by national authorities, 2017 Table 6: Total sales of meningococcal vaccines in the US, by risk group($ m), 2016 – 25 Table 7: Total sales of meningococcal vaccines in the US, by class($ m), 2016 – 25 Table 8: US meningococcal vaccines market forecast, 2016 – 25 Table 9: US meningococcal vaccination coverage rates in recommended risk groups, 2016 – 25 Table 10: Total sales of meningococcal vaccines in France, by class($ m), 2016 – 25 Table 11: France meningococcal vaccines market forecast, 2016 – 25 Table 12: France meningococcal vaccination coverage rates in recommended risk groups, 2016 – 25 Table 13: Total sales of meningococcal vaccines in Germany, by class($ m), 2016 – 25 Table 14: Germany meningococcal vaccines market forecast, 2016 – 25 Table 15: Germany meningococcal vaccination coverage rates in recommended risk groups, 2016 – 25 Table 16: Total sales of meningococcal vaccines in Italy, by class($ m), 2016 – 25 Table 17: Italy meningococcal vaccines market forecast, 2016 – 25 Table 18: Italy meningococcal vaccination coverage rates in recommended risk groups, 2016 – 25 Table 19: Total sales of meningococcal vaccines in Spain, by class($ m), 2016 – 25 Table 20: Spain meningococcal vaccines market forecast, 2016 – 25 Table 21: Spain meningococcal vaccination coverage rates in recommended risk groups, 2016 – 25